Analyzing RxSight (NASDAQ:RXST) & Bausch + Lomb (NYSE:BLCO)

RxSight (NASDAQ:RXSTGet Rating) and Bausch + Lomb (NYSE:BLCOGet Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares RxSight and Bausch + Lomb’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $22.59 million 15.76 -$48.69 million ($5.43) -2.38
Bausch + Lomb $3.77 billion 1.44 $182.00 million N/A N/A

Bausch + Lomb has higher revenue and earnings than RxSight.

Profitability

This table compares RxSight and Bausch + Lomb’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RxSight -212.04% -251.55% -37.22%
Bausch + Lomb N/A N/A N/A

Institutional & Insider Ownership

31.6% of RxSight shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for RxSight and Bausch + Lomb, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight 0 0 6 0 3.00
Bausch + Lomb 0 4 7 0 2.64

RxSight currently has a consensus target price of $19.83, suggesting a potential upside of 53.27%. Bausch + Lomb has a consensus target price of $23.33, suggesting a potential upside of 50.83%. Given RxSight’s stronger consensus rating and higher possible upside, equities analysts clearly believe RxSight is more favorable than Bausch + Lomb.

Summary

Bausch + Lomb beats RxSight on 6 of the 10 factors compared between the two stocks.

RxSight Company Profile (Get Rating)

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Bausch + Lomb Company Profile (Get Rating)

Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.